43.00
0.64 (1.51%)
| Penutupan Terdahulu | 42.36 |
| Buka | 42.49 |
| Jumlah Dagangan | 1,553,330 |
| Purata Dagangan (3B) | 1,037,241 |
| Modal Pasaran | 2,286,646,528 |
| Harga / Pendapatan (P/E Ke hadapan) | 384.62 |
| Harga / Jualan (P/S) | 8.97 |
| Harga / Buku (P/B) | 9.74 |
| Julat 52 Minggu |
| Margin Keuntungan | -3.68% |
| Margin Operasi (TTM) | -3.42% |
| EPS Cair (TTM) | -0.160 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 17.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 67.39% |
| Nisbah Semasa (MRQ) | 4.28 |
| Aliran Tunai Operasi (OCF TTM) | 3.62 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.84 M |
| Pulangan Atas Aset (ROA TTM) | -0.13% |
| Pulangan Atas Ekuiti (ROE TTM) | -7.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Menurun |
| Medical Devices (Global) | Bercampur | Menurun | |
| Stok | AxoGen, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.50 |
|
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.84% |
| % Dimiliki oleh Institusi | 86.20% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |